ClinicalTrials.gg
CompletedNCT04784533Updated Oct 9, 2024Results posted

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

A Phase 2 interventional study of CTP-543 and Placebo in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 39 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.

Enrollment
6th of 10
317 · median 336
Started
2021
with 2 others
Phase 2
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
6 of 10
Concert Pharmaceuticals

Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 6th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About deuruxolitinib

Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing deuruxolitinib in Alopecia Areata, or all of them as a file.
02

Study summary

This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

03

Conditions studied

  • Alopecia Areata

Browse trials for

Keywords

  • CTP-543
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
  • At least 50% scalp hair loss, as defined by a severity of alopecia tool (SALT) score ≥50, at Screening and Baseline.
  • Willing to comply with the study visits and requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.
  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.
  • Treatment with systemic medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
  • medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    Part A: Period 1 - CTP-543 8 mg BID

    Participants received CTP-543 8 milligrams (mg) tablets, orally, twice daily (BID) for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    Part A: Period 1 - CTP-543 12 mg BID

    Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID

    Participants who received CTP-543 8 mg during Period 1 of Part A and achieved an absolute severity of alopecia tool (SALT) score of ≤20 at Week 24, received CTP-543 4 mg tablets, orally, BID, for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID

    Participants who received CTP-543 12 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.

    Drug: CTP-543

  • Placebo comparator
    Part A: Period 2 - CTP-543 8 mg BID to Placebo

    Participants who received CTP-543 8 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 matched placebo tablets, orally, BID, for up to 24 weeks.

    Drug: Placebo

  • Placebo comparator
    Part A: Period 2 - CTP-543 12 mg BID to Placebo

    Participants who received CTP-543 12 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 matched placebo tablets, orally, BID, for up to 24 weeks.

    Drug: Placebo

  • Experimental
    Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID

    Participants who received CTP-543 8 mg during Period 1, followed by CTP-543 4 mg during Period 2 of Part A and met the criteria for loss of regrowth maintenance (LOM) (absolute SALT score of \> 20), received re-treatment with CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID

    Participants who received CTP-543 12 mg during Period 1, followed by CTP-543 8 mg during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 12 mg tablets, orally, BID, for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    Part B: CTP-543 8 mg BID to Placebo to 8 mg BID

    Participants who received CTP-543 8 mg during Period 1, followed by CTP-543 matched placebo during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    Part B: CTP-543 12 mg BID to Placebo to 12 mg BID

    Participants who received CTP-543 12 mg during Period 1, followed by CTP-543 matched placebo during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 12 mg tablets, orally, BID, for up to 24 weeks.

    Drug: CTP-543

Interventions

  • Oral dosing

  • DrugPlacebo

    Oral dosing

06

What researchers measure

Primary outcomes

  1. Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose Reduction

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose reduction conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was the end of Part A Period 2, where the last observed non-missing SALT value was selected for each participant.

    Time frame: From Week 24 to Week 48

  2. Part A, Period 2: Percentage of Participants Achieving LOM Criteria Defined by SALT Score > 20 Following Drug Discontinuation

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose discontinuation conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was at the end of Part A Period 2, where the last observed non-missing SALT value was selected for each participant.

    Time frame: From Week 24 to Week 48

  3. Part B: Percentage of Participants by Dose Group Who Achieved Restoration of Regrowth (ROR) at Week 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). ROR is defined as the participant's attainment of an absolute SALT score of ≤20 at Week 24 of re-treatment.

    Time frame: Week 24 of re-treatment

Secondary outcomes

  1. Part A, Period 2: Percentage of Participants Who Achieved LOM Criteria Defined by SALT Score > 20 Following Dose Reduction Conditions at Weeks 28, 32, 36, 40, 44, and 48

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20.

    Time frame: Weeks 28, 32, 36, 40, 44, and 48

  2. Part A, Period 2: Percentage of Participants Who Achieved LOM Criteria Defined by SALT > 20 Following Drug Discontinuation Conditions at Weeks 28, 32, 36, 40, 44, and 48

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20.

    Time frame: Weeks 28, 32, 36, 40, 44, and 48

  3. Part A, Period 1: Percentage of Responders as Assessed on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24

    SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. SPRO responder is defined as a post-baseline response of 'very satisfied' or 'satisfied'.

    Time frame: Weeks 12, 16, 20, and 24

  4. Part A, Period 1: Percentage of Participants Who Achieved an Absolute SALT Score ≤20 at Weeks 4, 8, 12, 16, 20, and 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  5. Part A, Period 1: Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score). Negative change indicates no hair loss.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  6. Part A, Period 1: Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20 and 24

    The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

    Time frame: Weeks 12, 16, 20, and 24

  7. Part A, Period 1: Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24

    The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved). PGI responder is a response of 'very much improved' or 'much improved'.

    Time frame: Weeks 12, 16, 20, and 24

  8. Part A, Period 1: Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

    The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  9. Part A, Period 1: Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

    The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  10. Part A, Period 1: Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24

    The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicates the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  11. Part B: Percentage of Participants Who Achieved Restoration of Regrowth Criteria at Weeks 4, 8, 12, 16, 20, and 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). ROR is defined as the participant's attainment of an absolute SALT score of ≤20 during re-treatment.

    Time frame: Weeks 4, 8, 12, 16, 20, and 24 of re-treatment

  12. Part B: Relative Change in SALT Scores From Part B Baseline at Weeks 4, 8, 12, 16, 20, and 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24 of re-treatment

  13. Number of Participants Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)

    An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event. TEAEs were defined as any adverse event that occurs after administration of the first dose of study drug in each Part/Period (ie, on or after the day of the first dose in each Part/Period). TEAEs included both serious and non-serious TEAEs.

    Time frame: From first dose of study drug up to last follow up visit (Week 76)

07

Results

Posted Oct 9, 2024

Participant flow

Participants were enrolled at study centers in the United States from 26 February 2021 to 16 May 2023.

Part A: Period 1 (Day 1 to Week 24)
Participant flow — Part A: Period 1 (Day 1 to Week 24)
MilestonePart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDPart A: Period 2 - CTP-543 8 mg BID to 4 mg BIDPart A: Period 2 - CTP-543 12 mg BID to 8 mg BIDPart A: Period 2 - CTP-543 8 mg BID to PlaceboPart A: Period 2 - CTP-543 12 mg BID to PlaceboPart B: CTP-543 8 mg BID to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
Started18013700000000
Efficacy population17813500000000
Completed16211800000000
Not completed181900000000
Withdrew: Treatment emergent or worsening adverse event6300000000
Withdrew: Lack of efficacy1100000000
Withdrew: Non-compliance with study drug0200000000
Withdrew: Protocol violation1000000000
Withdrew: Reason not specified5700000000
Withdrew: Lost to follow-up5600000000
Part A: Period 2 (Week 24 to Week 48)
Participant flow — Part A: Period 2 (Week 24 to Week 48)
MilestonePart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDPart A: Period 2 - CTP-543 8 mg BID to 4 mg BIDPart A: Period 2 - CTP-543 12 mg BID to 8 mg BIDPart A: Period 2 - CTP-543 8 mg BID to PlaceboPart A: Period 2 - CTP-543 12 mg BID to PlaceboPart B: CTP-543 8 mg BID to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
Started00182518250000
Completed00172518250000
Not completed0010000000
Withdrew: Lost to follow-up0010000000
Part B (Day 1 to Week 24)
Participant flow — Part B (Day 1 to Week 24)
MilestonePart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDPart A: Period 2 - CTP-543 8 mg BID to 4 mg BIDPart A: Period 2 - CTP-543 12 mg BID to 8 mg BIDPart A: Period 2 - CTP-543 8 mg BID to PlaceboPart A: Period 2 - CTP-543 12 mg BID to PlaceboPart B: CTP-543 8 mg BID to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
Started000000581519
Completed000000581318
Not completed0000000021
Withdrew: Lost to follow-up0000000010
Withdrew: Reason not specified0000000011

Outcome measures

PrimaryPart A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose Reduction

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose reduction conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was the end of Part A Period 2, where the last observed non-missing SALT value was selected for each participant.

Time frame:
From Week 24 to Week 48
Reported as:
Number · Percentage of participants
Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose Reduction
Percentage of participantsPart A: Period 2 - CTP-543 8 mg BID to 4 mg BIDPart A: Period 2 - CTP-543 12 mg BID to 8 mg BID
Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose Reduction27.8 (7.1 to 48.5)32.0 (13.7 to 50.3)
PrimaryPart A, Period 2: Percentage of Participants Achieving LOM Criteria Defined by SALT Score > 20 Following Drug Discontinuation

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose discontinuation conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was at the end of Part A Period 2, where the last observed non-missing SALT value was selected for each participant.

Time frame:
From Week 24 to Week 48
Reported as:
Number · Percentage of participants
Part A, Period 2: Percentage of Participants Achieving LOM Criteria Defined by SALT Score > 20 Following Drug Discontinuation
Percentage of participantsPart A: Period 2 - CTP-543 8 mg BID to PlaceboPart A: Period 2 - CTP-543 12 mg BID to Placebo
Part A, Period 2: Percentage of Participants Achieving LOM Criteria Defined by SALT Score > 20 Following Drug Discontinuation83.3 (66.1 to 100.0)80.0 (64.3 to 95.7)
PrimaryPart B: Percentage of Participants by Dose Group Who Achieved Restoration of Regrowth (ROR) at Week 24

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). ROR is defined as the participant's attainment of an absolute SALT score of ≤20 at Week 24 of re-treatment.

Time frame:
Week 24 of re-treatment
Reported as:
Number · Percentage of participants
Part B: Percentage of Participants by Dose Group Who Achieved Restoration of Regrowth (ROR) at Week 24
Percentage of participantsPart B: CTP-543 8 mg BID to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
Part B: Percentage of Participants by Dose Group Who Achieved Restoration of Regrowth (ROR) at Week 2460.0 (17.1 to 100.0)50.0 (15.4 to 84.6)66.7 (54.0 to 99.8)73.7 (58.6 to 97.0)
SecondaryPart A, Period 2: Percentage of Participants Who Achieved LOM Criteria Defined by SALT Score > 20 Following Dose Reduction Conditions at Weeks 28, 32, 36, 40, 44, and 48

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20.

Time frame:
Weeks 28, 32, 36, 40, 44, and 48
Reported as:
Number · Percentage of participants
Part A, Period 2: Percentage of Participants Who Achieved LOM Criteria Defined by SALT Score > 20 Following Dose Reduction Conditions at Weeks 28, 32, 36, 40, 44, and 48
Percentage of participantsPart A: Period 2 - CTP-543 8 mg BID to 4 mg BIDPart A: Period 2 - CTP-543 12 mg BID to 8 mg BID
Week 280 (NA to NA)12 (2.5 to 31.2)
Week 326.3 (0.2 to 30.2)4.5 (0.1 to 22.8)
Week 360 (NA to NA)4.8 (0.1 to 23.8)
Week 4012.5 (1.6 to 38.3)10.5 (1.3 to 33.1)
Week 447.7 (0.2 to 36.0)0 (NA to NA)
Week 487.7 (0.2 to 36.0)5.6 (0.1 to 27.3)
SecondaryPart A, Period 2: Percentage of Participants Who Achieved LOM Criteria Defined by SALT > 20 Following Drug Discontinuation Conditions at Weeks 28, 32, 36, 40, 44, and 48

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20.

Time frame:
Weeks 28, 32, 36, 40, 44, and 48
Reported as:
Number · Percentage of participants
Part A, Period 2: Percentage of Participants Who Achieved LOM Criteria Defined by SALT > 20 Following Drug Discontinuation Conditions at Weeks 28, 32, 36, 40, 44, and 48
Percentage of participantsPart A: Period 2 - CTP-543 8 mg to PlaceboPart A, Period 2 - CTP-543 12 mg to CTP-543 Matched Placebo
Week 280 (NA to NA)16.7 (4.7 to 37.4)
Week 3216.7 (3.6 to 41.4)14.3 (3.0 to 36.3)
Week 3626.7 (7.8 to 55.1)43.8 (19.8 to 70.1)
Week 4036.4 (10.9 to 69.2)22.2 (2.8 to 60.0)
Week 4428.6 (3.7 to 71.0)0 (NA to NA)
Week 4840.0 (5.3 to 85.3)28.6 (3.7 to 71.0)
SecondaryPart A, Period 1: Percentage of Responders as Assessed on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. SPRO responder is defined as a post-baseline response of 'very satisfied' or 'satisfied'.

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part A, Period 1: Percentage of Responders as Assessed on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
Percentage of participantsPart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BID
Week 1224.0 (17.6 to 30.4)40.2 (31.6 to 48.7)
Week 1626.9 (20.2 to 33.7)39.1 (30.6 to 47.5)
Week 2025.6 (18.9 to 32.3)52.0 (43.2 to 60.9)
Week 2428.8 (21.9 to 35.8)48.7 (39.8 to 57.7)
Statistical analysis
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 16.2 · 95% CI 5.5 to 26.8Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 12.1 · 95% CI 1.3 to 22.9Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 26.4 · 95% CI 15.4 to 37.5Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 19.9 · 95% CI 8.5 to 31.3Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
SecondaryPart A, Period 1: Percentage of Participants Who Achieved an Absolute SALT Score ≤20 at Weeks 4, 8, 12, 16, 20, and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).

Time frame:
Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part A, Period 1: Percentage of Participants Who Achieved an Absolute SALT Score ≤20 at Weeks 4, 8, 12, 16, 20, and 24
Percentage of participantsPart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BID
Week 40 (NA to NA)0 (NA to NA)
Week 81.7 (0.0 to 3.7)2.3 (0.0 to 5.0)
Week 125.8 (2.3 to 9.3)16.4 (10.0 to 22.8)
Week 1610.2 (5.6 to 14.8)24.2 (16.8 to 31.6)
Week 2015.9 (10.3 to 21.4)35.2 (26.8 to 43.7)
Week 2422.1 (15.7 to 28.5)42.9 (34.0 to 51.7)
Statistical analysis
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 0.6 · 95% CI -2.7 to 3.9Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 10.6 · 95% CI 3.3 to 17.9Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 14.0 · 95% CI 5.3 to 22.8Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 19.4 · 95% CI 9.2 to 29.5Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 20.8 · 95% CI 9.8 to 31.7Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
SecondaryPart A, Period 1: Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score). Negative change indicates no hair loss.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · Percent change
Part A, Period 1: Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
Percent changePart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BID
Relative Change From Baseline at Week 4-0.5 ± 11.17-1.0 ± 8.73
Relative Change From Baseline at Week 8-7.4 ± 18.41-14.8 ± 21.67
Relative Change From Baseline at Week 12-18.1 ± 27.42-30.9 ± 33.69
Relative Change From Baseline at Week 16-26.3 ± 31.68-39.9 ± 36.24
Relative Change From Baseline at Week 20-32.1 ± 34.26-49.0 ± 37.44
Relative Change From Baseline at Week 24-38.2 ± 36.85-55.3 ± 38.01
Statistical analysis
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Least square (ls) mean difference: -0.5 · 95% CI -2.8 to 1.8LS means,standard error(SE),and confidence intervals(CIs) are based on mixed model repeated measures(MMRM)analysis with effects for treatment,visit,treatment-by-visit interaction,and baseline value.The Model uses an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -7.3 · 95% CI -11.9 to -2.7LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -12.4 · 95% CI -19.3 to -5.5LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -14.6 · 95% CI -22.2 to -6.9LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -15.4 · 95% CI -23.7 to -7.2LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -15.4 · 95% CI -24.0 to -6.8LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
SecondaryPart A, Period 1: Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20 and 24

The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · Percentage of responders
Part A, Period 1: Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20 and 24
Percentage of respondersPart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BID
Week 1226.7 (20.1 to 33.4)47.6 (38.9 to 56.3)
Week 1637.7 (30.4 to 45.1)51.6 (42.9 to 60.2)
Week 2047.6 (39.2 to 55.2)63.1 (54.6 to 71.7)
Week 2450.3 (42.6 to 58.0)64.7 (56.1 to 73.3)
Statistical analysis
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 20.9 · 95% CI 9.9 to 31.8Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 13.8 · 95% CI 2.5 to 25.2Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 15.6 · 95% CI 4.1 to 27.0Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 14.4 · 95% CI 2.9 to 25.9Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
SecondaryPart A, Period 1: Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24

The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved). PGI responder is a response of 'very much improved' or 'much improved'.

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · Percentage of responders
Part A, Period 1: Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
Percentage of respondersPart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BID
Week 1229.8 (23.0 to 36.7)52.8 (44.1 to 61.4)
Week 1633.5 (26.4 to 40.7)55.5 (46.9 to 64.1)
Week 2040.9 (33.3 to 48.4)63.4 (54.9 to 71.9)
Week 2446.0 (38.4 to 53.7)65.5 (57.0 to 74.1)
Statistical analysis
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 22.9 · 95% CI 11.9 to 34.0Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 21.9 · 95% CI 10.7 to 33.1Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 22.6 · 95% CI 11.2 to 33.9Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Difference in percentages: 19.5 · 95% CI 8.1 to 31.0Treatment difference is calculated as the difference between the percentage of responders in the 12 mg BID group versus the 8 mg BID group.
SecondaryPart A, Period 1: Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · Score on a scale
Part A, Period 1: Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Score on a scalePart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BID
Baseline6.4 ± 0.786.3 ± 0.95
Change From Baseline at Week 12-0.8 ± 1.15-1.4 ± 1.63
Change From Baseline at Week 16-1.1 ± 1.37-1.8 ± 1.74
Change From Baseline at Week 20-1.3 ± 1.38-2.1 ± 1.84
Change From Baseline at Week 24-1.6 ± 1.64-2.4 ± 1.92
Statistical analysis
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.6 · 95% CI -0.9 to -0.3LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.7 · 95% CI -1.1 to -0.4LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.8 · 95% CI -1.2 to -0.4LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.7 · 95% CI -1.2 to -0.3LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value. The model is fit using an unstructured covariance structure.
SecondaryPart A, Period 1: Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · Score on a scale
Part A, Period 1: Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Score on a scalePart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BID
Baseline6.4 ± 0.756.4 ± 0.84
Change From Baseline at Week 12-0.8 ± 1.31-1.1 ± 1.56
Change From Baseline at Week 16-1.0 ± 1.41-1.6 ± 1.74
Change From Baseline at Week 20-1.1 ± 1.41-2.1 ± 1.78
Change From Baseline at Week 24-1.4 ± 1.66-2.3 ± 1.95
Statistical analysis
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Least square (ls) mean difference: -0.4 · 95% CI -0.7 to -0.1LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.7 · 95% CI -1.0 to -0.3LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.8 · 95% CI -1.2 to -0.5LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.8 · 95% CI -1.2 to -0.4LS means, SE, and CIs are based on an MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
SecondaryPart A, Period 1: Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24

The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicates the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · Score on a scale
Part A, Period 1: Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Score on a scalePart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BID
Satisfied Thickness Hair Coverage: Baseline4.6 ± 0.744.6 ± 0.67
Satisfied Thickness Hair Coverage: Change From Baseline at Week 12-0.9 ± 1.17-1.3 ± 1.15
Satisfied Thickness Hair Coverage: Change From Baseline at Week 16-1.0 ± 1.15-1.5 ± 1.14
Satisfied Thickness Hair Coverage: Change From Baseline at Week 20-1.1 ± 1.23-1.7 ± 1.16
Satisfied Thickness Hair Coverage: Change From Baseline at Week 24-1.2 ± 1.38-1.7 ± 1.25
Satisfied Evenness Hair Coverage: Baseline4.7 ± 0.624.7 ± 0.64
Satisfied Evenness Hair Coverage: Change From Baseline at Week 12-0.8 ± 1.09-1.3 ± 1.09
Satisfied Evenness Hair Coverage: Change From Baseline at Week 16-0.9 ± 1.07-1.4 ± 1.14
Satisfied Evenness Hair Coverage: Change From Baseline at Week 20-1.0 ± 1.11-1.6 ± 1.19
Satisfied Evenness Hair Coverage: Change From Baseline at Week 24-1.1 ± 1.22-1.7 ± 1.18
How Satisfied With Your Eyebrows: Baseline4.0 ± 1.234.1 ± 1.35
How Satisfied With Your Eyebrows: Change From Baseline at Week 12-0.8 ± 1.20-1.4 ± 1.43
How Satisfied With Your Eyebrows: Change From Baseline at Week 16-1.0 ± 1.17-1.4 ± 1.44
How Satisfied With Your Eyebrows: Change From Baseline at Week 20-1.0 ± 1.28-1.5 ± 1.32
How Satisfied With Your Eyebrows: Change From Baseline at Week 24-1.1 ± 1.29-1.7 ± 1.42
How Satisfied With Your Eyelashes: Baseline3.7 ± 1.403.7 ± 1.44
How Satisfied With Your Eyelashes: Change From Baseline at Week 12-0.7 ± 1.12-1.1 ± 1.42
How Satisfied With Your Eyelashes: Change From Baseline at Week 16-0.8 ± 1.25-1.3 ± 1.42
How Satisfied With Your Eyelashes: Change From Baseline at Week 20-0.8 ± 1.22-1.4 ± 1.37
How Satisfied With Your Eyelashes: Change From Baseline at Week 24-0.9 ± 1.28-1.5 ± 1.41
Statistical analysis
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.7 to -0.2LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.4 · 95% CI -0.7 to -0.2LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.8 to -0.3LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.8 to -0.2LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.8 to -0.3LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.7 to -0.3LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.6 · 95% CI -0.8 to -0.3LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.8 to -0.3LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.8 to -0.2LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.4 · 95% CI -0.6 to -0.1LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.4 · 95% CI -0.7 to -0.1LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.4 · 95% CI -0.7 to -0.2LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.7 to -0.2LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.7 to -0.2LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.7 to -0.2LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
  • Part A: Period 1 - CTP-543 8 mg BID vs Part A: Period 1 - CTP-543 12 mg BID · Ls mean difference: -0.5 · 95% CI -0.8 to -0.3LS means, SEs, and CIs are based on a mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score. The model is fit using an unstructured covariance structure.
SecondaryPart B: Percentage of Participants Who Achieved Restoration of Regrowth Criteria at Weeks 4, 8, 12, 16, 20, and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). ROR is defined as the participant's attainment of an absolute SALT score of ≤20 during re-treatment.

Time frame:
Weeks 4, 8, 12, 16, 20, and 24 of re-treatment
Reported as:
Number · Percentage of participants
Part B: Percentage of Participants Who Achieved Restoration of Regrowth Criteria at Weeks 4, 8, 12, 16, 20, and 24
Percentage of participantsPart B: CTP-543 8 mg to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
Week 460.0 (17.1 to 100.0)62.5 (29.0 to 96.0)26.7 (4.3 to 49.0)15.8 (0.0 to 32.2)
Week 8100.0 (100.0 to 100.0)62.5 (29.0 to 96.0)23.1 (0.2 to 46.0)16.7 (0.0 to 33.9)
Week 1280.0 (44.9 to 100.0)62.5 (29.0 to 96.0)30.8 (5.7 to 55.9)43.8 (19.4 to 68.1)
Week 1660.0 (17.1 to 100.0)62.5 (29.0 to 96.0)50.0 (21.7 to 78.3)61.1 (38.6 to 83.6)
Week 2060.0 (17.1 to 100.0)62.5 (29.0 to 96.0)69.2 (44.1 to 94.3)70.6 (48.9 to 92.2)
Week 2460.0 (17.1 to 100.0)50.0 (15.4 to 84.6)76.9 (54.0 to 99.8)77.8 (58.6 to 97.0)
SecondaryPart B: Relative Change in SALT Scores From Part B Baseline at Weeks 4, 8, 12, 16, 20, and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24 of re-treatment
Reported as:
Mean · Percent change
Part B: Relative Change in SALT Scores From Part B Baseline at Weeks 4, 8, 12, 16, 20, and 24
Percent changePart B: CTP-543 8 mg BID to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
Relative Change From Baseline at Week 4-20.8 ± 15.27-1.5 ± 69.4312.1 ± 39.4447.8 ± 71.19
Relative Change From Baseline at Week 8-39.6 ± 20.3326.2 ± 109.9710.5 ± 48.1047.1 ± 94.35
Relative Change From Baseline at Week 12-42.6 ± 27.06-2.6 ± 78.81-7.2 ± 84.4133.9 ± 119.41
Relative Change From Baseline at Week 16-48.8 ± 52.66-11.4 ± 78.88-13.4 ± 95.31-15.2 ± 116.20
Relative Change From Baseline at Week 20-54.8 ± 43.90-7.8 ± 83.35-29.2 ± 93.24-31.5 ± 108.97
Relative Change From Baseline at Week 24-39.3 ± 53.48-7.9 ± 81.41-39.3 ± 84.49-38.4 ± 105.80
SecondaryNumber of Participants Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)

An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event. TEAEs were defined as any adverse event that occurs after administration of the first dose of study drug in each Part/Period (ie, on or after the day of the first dose in each Part/Period). TEAEs included both serious and non-serious TEAEs.

Time frame:
From first dose of study drug up to last follow up visit (Week 76)
Reported as:
Count of participants · Participants
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDPart A: Period 2 - CTP-543 8 mg BID to 4 mg BIDPart A: Period 2 - CTP-543 12 mg BID to 8 mg BIDPart A: Period 2 - CTP-543 8 mg BID to PlaceboPart A: Period 2 - CTP-543 12 mg BID to PlaceboPart B: CTP-543 8 mg BID to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)124100912711251214

Adverse events

Collected over From first dose of study drug up to last follow up visit (Week 76). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Period 1 - CTP-543 8 mg BID0/180 (0%)1/180 (0.6%)91/180 (50.6%)
Part A: Period 1 - CTP-543 12 mg BID0/137 (0%)5/137 (3.6%)82/137 (59.9%)
Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID0/18 (0%)0/18 (0%)9/18 (50%)
Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID0/25 (0%)0/25 (0%)10/25 (40%)
Part A: Period 2 - CTP-543 8 mg BID to Placebo0/18 (0%)2/18 (11.1%)7/18 (38.9%)
Part A: Period 2 - CTP-543 12 mg BID to Placebo0/25 (0%)0/25 (0%)9/25 (36%)
Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID0/5 (0%)0/5 (0%)2/5 (40%)
Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID0/8 (0%)0/8 (0%)5/8 (62.5%)
Part B: CTP-543 8 mg BID to Placebo to 8 mg BID0/15 (0%)0/15 (0%)12/15 (80%)
Part B: CTP-543 12 mg BID to Placebo to 12 mg BID0/19 (0%)0/19 (0%)14/19 (73.7%)
Most frequent serious events
Most frequent serious events
EventPart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDPart A: Period 2 - CTP-543 8 mg BID to 4 mg BIDPart A: Period 2 - CTP-543 12 mg BID to 8 mg BIDPart A: Period 2 - CTP-543 8 mg BID to PlaceboPart A: Period 2 - CTP-543 12 mg BID to PlaceboPart B: CTP-543 8 mg BID to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
Crohn's DiseaseGastrointestinal disorders0/1800/1370/180/251/180/250/50/80/150/19
Suicidal IdeationPsychiatric disorders0/1800/1370/180/251/180/250/50/80/150/19
ThrombocytopeniaBlood and lymphatic system disorders0/1801/1370/180/250/180/250/50/80/150/19
ThrombocytosisBlood and lymphatic system disorders0/1801/1370/180/250/180/250/50/80/150/19
Malignant Melanoma in SituNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1801/1370/180/250/180/250/50/80/150/19
Ankle FractureInjury, poisoning and procedural complications0/1801/1370/180/250/180/250/50/80/150/19
Electrocardiogram T Wave InversionInvestigations0/1801/1370/180/250/180/250/50/80/150/19
Pancreatic Carcinoma MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1800/1370/180/250/180/250/50/80/150/19
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPart A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDPart A: Period 2 - CTP-543 8 mg BID to 4 mg BIDPart A: Period 2 - CTP-543 12 mg BID to 8 mg BIDPart A: Period 2 - CTP-543 8 mg BID to PlaceboPart A: Period 2 - CTP-543 12 mg BID to PlaceboPart B: CTP-543 8 mg BID to 4 mg BID to 8 mg BIDPart B: CTP-543 12 mg BID to 8 mg BID to 12 mg BIDPart B: CTP-543 8 mg BID to Placebo to 8 mg BIDPart B: CTP-543 12 mg BID to Placebo to 12 mg BID
COVID-19Infections and infestations23/18021/1373/185/250/180/250/51/84/154/19
Candida infectionInfections and infestations0/1800/1370/180/250/180/251/51/80/150/19
CostochondritisMusculoskeletal and connective tissue disorders0/1800/1370/180/250/180/251/50/80/150/19
AcneSkin and subcutaneous tissue disorders23/18017/1370/181/250/180/251/50/80/150/19
HeadacheNervous system disorders19/18020/1370/180/250/180/250/51/82/151/19
Upper respiratory tract infectionInfections and infestations11/1803/1370/183/251/181/250/50/82/151/19
Fungal skin infectionInfections and infestations0/1800/1370/180/250/180/250/51/80/150/19
NasopharyngitisInfections and infestations11/18010/1370/183/250/183/250/51/81/151/19
ArthralgiaMusculoskeletal and connective tissue disorders2/1802/1371/180/251/180/250/51/81/150/19
EczemaSkin and subcutaneous tissue disorders1/1802/1370/180/250/180/250/51/80/150/19

Baseline characteristics

All randomized participants included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(years)Part A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDTotal
Mean40.0 ± 14.0539.6 ± 13.2139.8 ± 13.68
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDTotal
Female11993212
Male6144105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDTotal
Hispanic or Latino131124
Not Hispanic or Latino167126293
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Period 1 - CTP-543 8 mg BIDPart A: Period 1 - CTP-543 12 mg BIDTotal
Race — Asian14923
Race — Black or African American412465
Race — Native Hawaiian or other Pacific Islander101
Race — White121102223
Race — Other325
08

Study locations

39 sites
  • Total Skin and Beauty Dermatology Center, PC
    Birmingham, Alabama 35205, United States
  • Center for Dermatology and Plastic Surgery/CCT Research
    Scottsdale, Arizona 85260, United States
  • Kern Research, Inc.
    Bakersfield, California 93301, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • University of California, Irvine
    Irvine, California 92697, United States
  • Quest Dermatology Research
    Northridge, California 91324, United States
  • Kaiser Permanente
    Oakland, California 94611, United States
  • Palmtree Clinical Research, Inc.
    Palm Springs, California 92262, United States
  • Kaiser Permanente
    San Francisco, California 94118, United States
  • Colorado Center for Dermatology and Skin Surgery
    Centennial, Colorado 80111, United States
  • Colorado Medical Research Center, Inc.
    Denver, Colorado 80210, United States
  • Yale University Church Street Research Unit
    New Haven, Connecticut 06519, United States
  • Skin Care Research, LLC
    Boca Raton, Florida 33486, United States
  • Skin Care Research, LLC
    Hollywood, Florida 33021, United States
  • DeNova Research
    Chicago, Illinois 60611, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Michigan Center for Research Company, LLC
    Clarkston, Michigan 48346, United States
  • University of Minnesota Department of Dermatology
    Minneapolis, Minnesota 55455, United States
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Skin Laser and Surgery Specialists of New Jersey
    Hackensack, New Jersey 07601, United States
  • Darst Dermatology
    Charlotte, North Carolina 28277, United States
  • Dermatology Specialists of Charlotte
    Charlotte, North Carolina 28277, United States
  • North Carolina Dermatology Associates, PLLC
    Raleigh, North Carolina 27617, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • Remington Davis
    Columbus, Ohio 43215, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 74136, United States
  • Northwest Dermatology
    Portland, Oregon 97210, United States
  • Dermatology Associates of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • PEAK Research, LLC
    Upper Saint Clair, Pennsylvania 15241, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Dermatology Treatment and Research Center, PA
    Dallas, Texas 75230, United States
  • Austin Institute for Clinical Research
    Houston, Texas 77056, United States
  • Austin Institute for Clinical Research, Inc.
    Pflugerville, Texas 78660, United States
  • Springville Dermatology/CCT Research
    Springville, Utah 84663, United States
  • West End Dermatology Associates
    Richmond, Virginia 23233, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2023, 26 months.

Results were first posted in Oct 2024, 1 year 4 months after primary completion. A results delay was requested in Apr 2024.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 5, 2021
StartActual
Feb 26, 2021
Primary completionActual
May 16, 2023
CompletionActual
May 16, 2023
Results delay requested
Apr 4, 2024
Results first posted
Oct 9, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04784533
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Feb 26, 2021
Primary completion
May 16, 2023
Completion
May 16, 2023
Results posted
Oct 9, 2024
Last update
Oct 9, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion